|
|||||||
|
Fusion Protein:BARD1-ITGAV |
Fusion Gene and Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: BARD1-ITGAV | FusionPDB ID: 8979 | FusionGDB2.0 ID: 8979 | Hgene | Tgene | Gene symbol | BARD1 | ITGAV | Gene ID | 580 | 3685 |
| Gene name | BRCA1 associated RING domain 1 | integrin subunit alpha V | |
| Synonyms | - | CD51|MSK8|VNRA|VTNR | |
| Cytomap | 2q35 | 2q32.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | BRCA1-associated RING domain protein 1BRCA1-associated RING domain gene 1RING-type E3 ubiquitin transferase BARD1 | integrin alpha-Vantigen identified by monoclonal antibody L230integrin alphaVbeta3integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)vitronectin receptor subunit alpha | |
| Modification date | 20200322 | 20200313 | |
| UniProtAcc | Q99728 Main function of 5'-partner protein: FUNCTION: E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Plays a central role in the control of the cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3' cleavage. {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, ECO:0000269|PubMed:20351172}. | P06756 Main function of 5'-partner protein: FUNCTION: The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed:28302677). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed:29030430). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 and ITGAV:ITGB6 act as a receptor for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881). Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation (PubMed:15184403, PubMed:22278742, PubMed:28117447). ITGAV:ITGB3 act as a receptor for CD40LG (PubMed:31331973). {ECO:0000269|PubMed:12807887, ECO:0000269|PubMed:15184403, ECO:0000269|PubMed:17158881, ECO:0000269|PubMed:18441324, ECO:0000269|PubMed:18635536, ECO:0000269|PubMed:19578119, ECO:0000269|PubMed:20682778, ECO:0000269|PubMed:22278742, ECO:0000269|PubMed:23125415, ECO:0000269|PubMed:25398877, ECO:0000269|PubMed:28117447, ECO:0000269|PubMed:28302677, ECO:0000269|PubMed:28873464, ECO:0000269|PubMed:29030430, ECO:0000269|PubMed:31331973}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB5 acts as a receptor for Adenovirus type C. {ECO:0000269|PubMed:20615244}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB5 and ITGAV:ITGB3 act as receptors for Coxsackievirus A9 and B1. {ECO:0000269|PubMed:15194773, ECO:0000269|PubMed:7519807, ECO:0000269|PubMed:9426447}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Herpes virus 8/HHV-8. {ECO:0000269|PubMed:18045938}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB6 acts as a receptor for herpes simplex 1/HHV-1. {ECO:0000269|PubMed:24367260}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Human parechovirus 1. {ECO:0000269|PubMed:11160695}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for West nile virus. {ECO:0000269|PubMed:23658209}.; FUNCTION: (Microbial infection) In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. {ECO:0000269|PubMed:10397733}. | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000260947, ENST00000449967, ENST00000432456, ENST00000471787, | ENST00000474571, ENST00000261023, ENST00000374907, ENST00000433736, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 3 X 4 X 3=36 | 9 X 8 X 6=432 |
| # samples | 4 | 9 | |
| ** MAII score | log2(4/36*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(9/432*10)=-2.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Fusion gene context | PubMed: BARD1 [Title/Abstract] AND ITGAV [Title/Abstract] AND fusion [Title/Abstract] | ||
| Fusion neoantigen context | PubMed: BARD1 [Title/Abstract] AND ITGAV [Title/Abstract] AND neoantigen [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | BARD1(215632205)-ITGAV(187466747), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | BARD1-ITGAV seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BARD1-ITGAV seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BARD1-ITGAV seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. BARD1-ITGAV seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. BARD1-ITGAV seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. BARD1-ITGAV seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF. BARD1-ITGAV seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. BARD1-ITGAV seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF. BARD1-ITGAV seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. BARD1-ITGAV seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | BARD1 | GO:0046826 | negative regulation of protein export from nucleus | 15265711 |
| Hgene | BARD1 | GO:0085020 | protein K6-linked ubiquitination | 12890688|20351172 |
| Tgene | ITGAV | GO:0007155 | cell adhesion | 10218736 |
| Tgene | ITGAV | GO:0008284 | positive regulation of cell proliferation | 19578119 |
| Tgene | ITGAV | GO:0033627 | cell adhesion mediated by integrin | 12807887|17158881 |
| Tgene | ITGAV | GO:0034446 | substrate adhesion-dependent cell spreading | 24658351 |
| Tgene | ITGAV | GO:0045785 | positive regulation of cell adhesion | 10708943 |
| Tgene | ITGAV | GO:0050764 | regulation of phagocytosis | 10570297 |
| Tgene | ITGAV | GO:0070588 | calcium ion transmembrane transport | 18395422 |
| Tgene | ITGAV | GO:1901388 | regulation of transforming growth factor beta activation | 22278742 |
| Tgene | ITGAV | GO:2000536 | negative regulation of entry of bacterium into host cell | 10570297 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:215632205/chr2:187466747) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here. |
| Fusion gene breakpoints across BARD1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across ITGAV (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Amino Acid Sequences |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000260947 | BARD1 | chr2 | 215632205 | - | ENST00000261023 | ITGAV | chr2 | 187466747 | + | 8274 | 1703 | 3 | 4664 | 1553 |
| ENST00000260947 | BARD1 | chr2 | 215632205 | - | ENST00000374907 | ITGAV | chr2 | 187466747 | + | 8162 | 1703 | 3 | 4556 | 1517 |
| ENST00000260947 | BARD1 | chr2 | 215632205 | - | ENST00000433736 | ITGAV | chr2 | 187466747 | + | 4814 | 1703 | 3 | 4664 | 1553 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000260947 | ENST00000261023 | BARD1 | chr2 | 215632205 | - | ITGAV | chr2 | 187466747 | + | 4.86E-05 | 0.9999515 |
| ENST00000260947 | ENST00000374907 | BARD1 | chr2 | 215632205 | - | ITGAV | chr2 | 187466747 | + | 5.54E-05 | 0.99994457 |
| ENST00000260947 | ENST00000433736 | BARD1 | chr2 | 215632205 | - | ITGAV | chr2 | 187466747 | + | 0.000278301 | 0.9997217 |
| Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones. |
Get the fusion protein sequences from here. |
| Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for BARD1-ITGAV |
| +/-13 AA sequence from the breakpoints of the fusion protein sequences. |
| Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
| BARD1 | chr2 | 215632205 | ITGAV | chr2 | 187466747 | 1703 | 567 | KLLLSYGASRNAVRMFLLVGAPKANT |
Top |
Potential FusionNeoAntigen Information of BARD1-ITGAV in HLA I |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| BARD1-ITGAV_215632205_187466747.msa |
| Potential FusionNeoAntigen Information * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:02 | SRNAVRMFL | 0.9995 | 0.5319 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:04 | SRNAVRMFL | 0.9995 | 0.7005 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:05 | SRNAVRMFL | 0.9994 | 0.8517 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B39:01 | SRNAVRMFL | 0.9953 | 0.8822 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B57:01 | ASRNAVRMF | 0.9947 | 0.9762 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B14:02 | SRNAVRMFL | 0.9941 | 0.6401 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B14:01 | SRNAVRMFL | 0.9941 | 0.6401 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B15:17 | ASRNAVRMF | 0.9926 | 0.8791 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B58:02 | ASRNAVRMF | 0.9892 | 0.9486 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B15:16 | ASRNAVRMF | 0.985 | 0.6927 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B38:02 | SRNAVRMFL | 0.9841 | 0.9518 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B57:03 | ASRNAVRMF | 0.9665 | 0.9784 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B39:06 | VRMFLLVGA | 0.9607 | 0.7626 | 12 | 21 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-A30:08 | ASRNAVRMF | 0.757 | 0.8303 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B15:37 | SRNAVRMFL | 0.5146 | 0.6204 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:04 | SRNAVRMFLL | 0.9999 | 0.6969 | 8 | 18 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:05 | SRNAVRMFLL | 0.9999 | 0.8172 | 8 | 18 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:95 | SRNAVRMF | 0.9999 | 0.7971 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:05 | SRNAVRMF | 0.9998 | 0.9747 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:27 | SRNAVRMF | 0.9996 | 0.9684 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:19 | SRNAVRMF | 0.9982 | 0.8323 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:46 | SRNAVRMF | 0.9982 | 0.9383 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C12:16 | SRNAVRMF | 0.9799 | 0.9695 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:14 | SRNAVRMFL | 0.9994 | 0.8131 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:95 | SRNAVRMFL | 0.9985 | 0.7611 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B73:01 | VRMFLLVGA | 0.9982 | 0.6571 | 12 | 21 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:05 | SRNAVRMFL | 0.9977 | 0.973 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B39:09 | SRNAVRMFL | 0.9969 | 0.6754 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B39:12 | SRNAVRMFL | 0.9948 | 0.8857 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:27 | SRNAVRMFL | 0.9937 | 0.965 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:13 | SRNAVRMFL | 0.9934 | 0.9281 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:29 | SRNAVRMFL | 0.99 | 0.9511 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:03 | SRNAVRMFL | 0.9711 | 0.8796 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:46 | SRNAVRMFL | 0.9707 | 0.9175 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:19 | SRNAVRMFL | 0.9422 | 0.7735 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:80 | SRNAVRMFL | 0.9338 | 0.9625 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:67 | SRNAVRMFL | 0.9338 | 0.9625 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B73:01 | SRNAVRMFL | 0.9233 | 0.6038 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C15:04 | ASRNAVRMF | 0.9105 | 0.9057 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:10 | SRNAVRMFL | 0.9009 | 0.9611 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C12:12 | ASRNAVRMF | 0.669 | 0.9559 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C12:04 | ASRNAVRMF | 0.4596 | 0.997 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B14:03 | SRNAVRMFL | 0.4438 | 0.7169 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C06:03 | ASRNAVRMF | 0.4297 | 0.9967 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C12:16 | SRNAVRMFL | 0.0799 | 0.9597 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:03 | SRNAVRMFLL | 0.9977 | 0.8535 | 8 | 18 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:01 | SRNAVRMF | 0.9999 | 0.7594 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:22 | SRNAVRMF | 0.9993 | 0.8361 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C06:08 | SRNAVRMF | 0.9979 | 0.9883 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C06:06 | SRNAVRMF | 0.976 | 0.991 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C06:02 | SRNAVRMF | 0.9637 | 0.9952 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C06:17 | SRNAVRMF | 0.9637 | 0.9952 | 8 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:06 | SRNAVRMFL | 0.9996 | 0.6858 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:10 | SRNAVRMFL | 0.9995 | 0.8679 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:08 | SRNAVRMFL | 0.9994 | 0.7198 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:09 | SRNAVRMFL | 0.9991 | 0.8164 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:01 | SRNAVRMFL | 0.9985 | 0.7219 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B39:31 | SRNAVRMFL | 0.9955 | 0.8819 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B57:10 | ASRNAVRMF | 0.9947 | 0.9762 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B57:04 | ASRNAVRMF | 0.9944 | 0.6934 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B58:06 | ASRNAVRMF | 0.9932 | 0.8581 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:17 | SRNAVRMFL | 0.9902 | 0.9769 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C06:08 | SRNAVRMFL | 0.9672 | 0.9848 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B15:24 | ASRNAVRMF | 0.9573 | 0.9204 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:02 | SRNAVRMFL | 0.9338 | 0.9625 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C15:09 | ASRNAVRMF | 0.9105 | 0.9057 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:04 | SRNAVRMFL | 0.8724 | 0.927 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C07:22 | SRNAVRMFL | 0.8573 | 0.7934 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-A30:01 | ASRNAVRMF | 0.7841 | 0.9376 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C16:04 | ASRNAVRMF | 0.7247 | 0.9837 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C12:03 | ASRNAVRMF | 0.6856 | 0.9892 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C03:67 | SRNAVRMFL | 0.5529 | 0.9834 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C06:06 | SRNAVRMFL | 0.3722 | 0.9911 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C16:01 | ASRNAVRMF | 0.3193 | 0.9889 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C02:10 | ASRNAVRMF | 0.2271 | 0.9889 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C02:02 | ASRNAVRMF | 0.2271 | 0.9889 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C16:02 | ASRNAVRMF | 0.0925 | 0.9961 | 7 | 16 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C06:17 | SRNAVRMFL | 0.0831 | 0.995 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-C06:02 | SRNAVRMFL | 0.0831 | 0.995 | 8 | 17 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:08 | SRNAVRMFLL | 0.9999 | 0.6793 | 8 | 18 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:10 | SRNAVRMFLL | 0.9999 | 0.8618 | 8 | 18 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:09 | SRNAVRMFLL | 0.9997 | 0.7727 | 8 | 18 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | HLA-B27:06 | SRNAVRMFLL | 0.9997 | 0.6823 | 8 | 18 |
Top |
Potential FusionNeoAntigen Information of BARD1-ITGAV in HLA II |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| BARD1-ITGAV_215632205_187466747.msa |
| Potential FusionNeoAntigen Information * We used NetMHCIIpan v4.1 (%rank<0.5). |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0101 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0105 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0107 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0109 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0113 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0115 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0117 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0119 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0121 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0125 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0127 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0129 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0131 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-0454 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1446 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1527 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1534 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1601 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1601 | NAVRMFLLVGAPKAN | 10 | 25 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1602 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1603 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1603 | NAVRMFLLVGAPKAN | 10 | 25 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1604 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1604 | NAVRMFLLVGAPKAN | 10 | 25 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1605 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1607 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1608 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1608 | NAVRMFLLVGAPKAN | 10 | 25 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1609 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1610 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1611 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1612 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1614 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB1-1616 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB5-0102 | AVRMFLLVGAPKANT | 11 | 26 |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 | DRB5-0108N | AVRMFLLVGAPKANT | 11 | 26 |
Top |
Fusion breakpoint peptide structures of BARD1-ITGAV |
| 3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
| File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
| 2672 | GASRNAVRMFLLVG | BARD1 | ITGAV | chr2 | 215632205 | chr2 | 187466747 | 1703 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of BARD1-ITGAV |
| Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens * We used Glide to predict the interaction between HLAs and neoantigens. |
| HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
| HLA-B14:02 | 3BVN | 2672 | GASRNAVRMFLLVG | -7.9962 | -8.1096 |
| HLA-B14:02 | 3BVN | 2672 | GASRNAVRMFLLVG | -5.70842 | -6.74372 |
| HLA-B52:01 | 3W39 | 2672 | GASRNAVRMFLLVG | -6.83737 | -6.95077 |
| HLA-B52:01 | 3W39 | 2672 | GASRNAVRMFLLVG | -4.4836 | -5.5189 |
| HLA-A11:01 | 4UQ2 | 2672 | GASRNAVRMFLLVG | -10.0067 | -10.1201 |
| HLA-A11:01 | 4UQ2 | 2672 | GASRNAVRMFLLVG | -9.03915 | -10.0745 |
| HLA-A24:02 | 5HGA | 2672 | GASRNAVRMFLLVG | -6.56204 | -6.67544 |
| HLA-A24:02 | 5HGA | 2672 | GASRNAVRMFLLVG | -5.42271 | -6.45801 |
| HLA-B44:05 | 3DX8 | 2672 | GASRNAVRMFLLVG | -7.85648 | -8.89178 |
| HLA-B44:05 | 3DX8 | 2672 | GASRNAVRMFLLVG | -5.3978 | -5.5112 |
| HLA-A02:01 | 6TDR | 2672 | GASRNAVRMFLLVG | -3.37154 | -4.40684 |
Top |
Vaccine Design for the FusionNeoAntigens of BARD1-ITGAV |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 12 | 21 | VRMFLLVGA | TGTCCGGATGTTTCTTCTCGTGGGAGC |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 7 | 16 | ASRNAVRMF | AGCCTCCAGAAATGCTGTCCGGATGTT |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 8 | 16 | SRNAVRMF | CTCCAGAAATGCTGTCCGGATGTT |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 8 | 17 | SRNAVRMFL | CTCCAGAAATGCTGTCCGGATGTTTCT |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 8 | 18 | SRNAVRMFLL | CTCCAGAAATGCTGTCCGGATGTTTCTTCT |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 10 | 25 | NAVRMFLLVGAPKAN | AAATGCTGTCCGGATGTTTCTTCTCGTGGGAGCTCCCAAAGCAAA |
| BARD1-ITGAV | chr2 | 215632205 | chr2 | 187466747 | 11 | 26 | AVRMFLLVGAPKANT | TGCTGTCCGGATGTTTCTTCTCGTGGGAGCTCCCAAAGCAAACAC |
Top |
Information of the samples that have these potential fusion neoantigens of BARD1-ITGAV |
| These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens. |
| Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
| STAD | BARD1-ITGAV | chr2 | 215632205 | ENST00000260947 | chr2 | 187466747 | ENST00000261023 | TCGA-BR-8589 |
Top |
Potential target of CAR-T therapy development for BARD1-ITGAV |
| Predicted 3D structure. We used RoseTTAFold. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features * Minus value of BPloci means that the break point is located before the CDS. |
| - In-frame and retained 'Transmembrane'. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | ITGAV | chr2:215632205 | chr2:187466747 | ENST00000261023 | 0 | 30 | 993_1016 | 0 | 1049.0 | Transmembrane | Helical | |
| Tgene | ITGAV | chr2:215632205 | chr2:187466747 | ENST00000374907 | 0 | 28 | 993_1016 | 0 | 1013.0 | Transmembrane | Helical | |
| Tgene | ITGAV | chr2:215632205 | chr2:187466747 | ENST00000433736 | 0 | 30 | 993_1016 | 0 | 1003.0 | Transmembrane | Helical |
| Subcellular localization prediction of the transmembrane domain retained fusion proteins * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
| Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
| BARD1 | chr2 | 215632205 | ENST00000260947 | ITGAV | chr2 | 187466747 | ENST00000261023 |  |
| BARD1 | chr2 | 215632205 | ENST00000260947 | ITGAV | chr2 | 187466747 | ENST00000374907 |  |
Top |
Related Drugs to BARD1-ITGAV |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to BARD1-ITGAV |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2023-PresentThe University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information
Campus Carry|Site Policies